share_log

金斯瑞生物科技(01548):传奇生物宣布欧盟委员会批准 CARVYKTI 用于复发难治性多发性骨髓瘤患者二线治疗

Kingsley Biotech (01548): Legendary Biotech announced that the European Commission approved CARVYKTI for second-line treatment of patients with recurrent refractory multiple myeloma

Zhitong Finance ·  Apr 22 20:44

Kingsley Biotech (01548) announced that Legend Biotech, a non-wholly-owned subsidiary of the company, was released in 2024...

Zhitong Finance App News, Kingsley Biotech (01548) announced that Legend Biotech, a non-wholly-owned subsidiary of the company, submitted Form 6-K to the US Securities Regulatory Commission (SEC) on April 22, 2024 (New York time, before the Hong Kong trading session on April 23, 2024), and the European Commission has approved CARVYKTI (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with recurrent refractory multiple myeloma. These patients have received at least one treatment before (including proteasome inhibitors (PIs) and an immunomodulator (IMID)), patients showed disease progression during the last treatment and were resistant to lenalidomide.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment